Freezing lung nodules: a new hope for inoperable patients?

NCT ID NCT07232433

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a procedure called cryoablation, which uses extreme cold to freeze and destroy lung nodules that are early-stage cancer. It is for people who cannot have surgery due to age or health issues. The trial will enroll 90 participants and follow them for up to 5 years to see if the cancer comes back and how safe the procedure is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cryoablation (a procedure that freezes and destroys cancer cells)
What this could lead to: If successful, this could provide a safe and effective treatment option for people with early-stage lung cancer who are not candidates for surgery.
What could go wrong: This is a small, early-phase study with no control group, so results may not be definitive. Risks include pneumothorax, bleeding, or infection from the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200025, China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.